Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. gained 0.710% compared to yesterday.
Our community is currently high on Akebia Therapeutics Inc. with 8 Buy predictions and 3 Sell predictions.
Based on the current price of 1.28 € the target price of 3 € shows a potential of 134.19% for Akebia Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Akebia Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | 0.710% | -2.511% | -36.269% | 114.573% | 9.300% | -49.567% | - |
| Ardelyx Inc. | 0.130% | -5.482% | -15.972% | 32.578% | 3.218% | -12.905% | - |
| Salarius Pharmaceuticals Inc. | 0.950% | -0.935% | -18.462% | -68.120% | -23.604% | -98.261% | -99.994% |
| Brainstorm Cell | 1.170% | -0.896% | -1.485% | -81.710% | 114.440% | -80.717% | - |
Comments
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $5.00 to $6.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The
